Roche Receives CE Mark for Alzheimer’s Disease Blood Test
Roche has received CE mark approval for its Elecsys pTau217 blood test, designed to aid in Alzheimer’s disease diagnosis by detecting amyloid pathology in patients with cognitive decline.
Latest Articles
Editor's Top Picks
How Labs Are Driving the Andes Hantavirus Outbreak Response
Laboratories are leveraging established diagnostic and surveillance tools to track the Andes hantavirus outbreak linked to a cruise ship, with experts noting no evidence of widespread community transmission or efficient airborne spread.
Be the First to Know What’s Next in the Lab
Every week, we dig into the biggest shifts, breakthroughs, and tech transforming clinical diagnostics. Straightforward, insightful, and always relevant.Critical Resources
Diagnostic Innovations
Fujirebio Receives CE Mark for New Alzheimer’s Disease Plasma Assay
Fujirebio Europe has received CE marking for its automated Lumipulse G pTau 217 Plasma assay, designed to help identify amyloid pathology in patients with cognitive decline, according to the company.
Equipment & Supply Spotlight
Invivoscribe Launches Automated System Integrating Nucleic Acid Extraction and Quantification
Invivoscribe, in collaboration with Hitachi High-Tech, has launched the PrepQuant System, an automated platform that integrates nucleic acid extraction, concentration, and quantification to streamline molecular testing workflows.
News, Know-How & Standards
Disease Detection & Understanding
Artera Receives CE Marks for AI-Powered Prostate and Breast Cancer Tests
Artera has received CE marks under EU IVDR for its AI-powered prostate and breast cancer assays, enabling clinical use of these prognostic and predictive tests in the European Union and other territories, the company announced.
